OX-2 membrane glycoprotein (CD200/MOX1)
EUPROTEIN has developed and validated CD200/OX-2 membrane glycoprotein that could be potentially used in the anti-cancer drug discovery.
Background
CD200, also known as OX-2 membrane glycoprotein, is a type-1 membrane glycoprotein, which contains two immunoglobulin domains and thus belongs to the immunoglobulin superfamily. This protein costimulates T-cell proliferation and may regulate myeloid cell activity in a variety of tissues. CD200 is also believed to regulate immune responses by negative regulation of macrophage activation.
Implication of CD200/OX-2 in Cancer Immunology
CD200 is shown to suppress the immune system’s responses to cancer in mainly three ways:
- Tumors actively shed the CD200/OX-2 membrane glycoprotein into the circulation
- Tumor associated blood vessels become lined with CD200, inactivating T-Cells as they try to enter the tumor environment
- Current tumor derived vaccines actually are chocked full of CD200 which quashes the immune response
To neutralize the immune suppression by CD200, scientists have been working on applying inhibitory peptide to activate the immune system through a CD200 activation receptor. Alternatively, anti-CD200 receptor antibodies could allow tumor-killing cells to pass through the blood vessel walls, enabling natural killing activities.
EUPROTEIN Offering
EUPROTEIN has developed and validated CD200/OX-2 membrane glycoprotein that could be potentially used in the anti-cancer drug discovery. This high-quality protein might also be applied in future development of diagnostic assays for tumors or therapies involved CD200/OX-2.
Fig 1. Human OX-2 Membrane Glycoprotein from Human Expi293 cells
Fig 2. Human OX-2 Membrane Glycoprotein with a Human IgG1 Fc tag
Or if you need help expressing the CD200/MOX1/OX-2 protein, please click to inquire